VMT01/02 (Combination with Nivolumab)
Melanoma (MC1R Imaging & Therapy)
Phase 1/2Enrolling 3.0 mCi
Key Facts
Indication
Melanoma (MC1R Imaging & Therapy)
Phase
Phase 1/2
Status
Enrolling 3.0 mCi
Company
About Perspective Therapeutics
Perspective Therapeutics is on a mission to transform cancer treatment with its innovative, image-guided targeted alpha-particle therapy platform. Formed in February 2023 from the merger of Viewpoint Molecular Targeting and Isoray, the company leverages proprietary Pb-212-based radiotherapies and a matched imaging agent (Pb-203) for a precise theranostic approach. Its clinical pipeline includes programs for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01/02), and fibroblast activation protein (PSV359) positive solid tumors, positioning it at the forefront of the next generation of radiopharmaceuticals.
View full company profileTherapeutic Areas
Other Melanoma (MC1R Imaging & Therapy) Drugs
| Drug | Company | Phase |
|---|---|---|
| VMT01/02 (Monotherapy) | Perspective Therapeutics | Phase 1/2 |